Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 543321 | NSE Symbol : TATVA | ISIN : INE0GK401011 | Industry : Chemicals |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
17-Jan-2025	28-Jan-2025	Quarterly Results	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2024. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 January 2025 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended 31 December 2024 Outcome of the Board Meeting held on 28.01.2025 (As Per BSE Announcement dated on 28.01.2025)
16-Oct-2024	25-Oct-2024	Quarterly Results	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2024. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 October 2024 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take the above intimation on your record and oblige. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended 30 September 2024 (As Per BSE Announcement dated on 25.10.2024)
16-Jul-2024	24-Jul-2024	Accounts	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2024 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2024. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 July 2024 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended on 30 June 2024. Outcome Of The Board Meeting Held On 24.07.2024 (As per BSE Announcement Dated on 24/07/2024)
24-Apr-2024	03-May-2024	Accounts	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/05/2024 ,inter alia, to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2024; 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended 31 March 2024, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its ''''designated persons'''' regarding the closure of the Trading Window for trading in the Company''s equity shares from 01 April 2024 till the expiry of 48 hours from the date the said financial results are made public. Board Meeting Outcome for Outcome Of The Board Meeting Held On 03.05.2024 1. Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and financial year ended 31 March 2024. In this regard, please find enclosed: The Board Recommended a Final Dividend of Rs. 2/- (20%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 23,39,20,550/- (2,33,92,055 equity shares of Rs. 10/- each) for the financial year 2023-24. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. Audited Financial Results (Standalone and Consolidated) Of The Company For the Quarter And Financial Year Ended On 31 March 2024. (As Per BSE Announcement Dated on 03.05..2024)
11-Jan-2024	20-Jan-2024	Quarterly Results	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/01/2024 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine month ended 31 December 2023. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 January 2024 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2023. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 20 January 2024. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of SEBI Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 12:15 P.M. and concluded at 03:15 P.M. Unaudited Financial Results (Standalone and Consolidated) of the Company for the Quarter and Nine Months ended on 31 December 2023 (As per BSE Announcement Dated on 20/01/2024) Newspaper Publication of Extract of Financial Results of the Company for the Quarter and Nine Months ended 31 December 2023. (As Per BSE Announcement Dated on 21/01/2024)
20-Oct-2023	02-Nov-2023	Quarterly Results	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2023 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2023. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 October 2023 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2023. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 02 November 2023. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of SEBI Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 11:45 A.M. and concluded at 03:35 P.M. Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended On 30 September 2023 (As Per BSE Announcement Dated on 02.11.2023)
27-Jul-2023	04-Aug-2023	Quarterly Results	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/08/2023 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2023. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 July 2023 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2023. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 August 2023. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of SEBI Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 11:30 A.M. and concluded at 02:45 P.M. (As per BSE Announcement Dated on 04/08/2023)
06-Jul-2023	11-Jul-2023	Raising of Capital	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/07/2023 inter alia to consider and approve Fund Raising and other business transactions as applicable. Outcome of the Board Meeting held on 11 July 2023 (As per BSE Announcement Dated on 11/07/2023)
25-Apr-2023	05-May-2023	Accounts	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2023 inter alia to consider and approve 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31 March 2023; 2. consider and recommend a final dividend if any on the equity shares of the Company for the financial year ended 31 March 2023 subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 April 2023 till the expiry of 48 hours from the date the said financial results are made public. The above information shall be uploaded on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige. Outcome Of The Board Meeting Held On 05.05.2023 The Board Recommended a Final Dividend of Rs. 2/- (20%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 22,16,50,620/- (2,21,65,062 equity shares of Rs. 10/- each) for the financial year 2022-23. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. Based on the recommendation made by the Audit Committee, the Board of Directors of the Company recommended the re-appointment of M/s NDJ & Co., (Firm Registration No.: 136345W), Chartered Accountants, Surat, as the Statutory Auditors of the Company for a second term of 5 (five) consecutive years from the conclusion of the ensuing 27th Annual General Meeting of the Company till the conclusion of the 32nd Annual General Meeting of the Company to be held in the year 2028, subject to the approval of the shareholders of the Company. (As Per BSE Announcement Dated on 05.05.2023)
13-Jan-2023	24-Jan-2023	Quarterly Results	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 January 2023 till the expiry of 48 hours from the date the said financial results are made public. The above information shall be made available on the website of the Company at www.tatvachintan.com. Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 24 January 2023. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 12:30 P.M. and concluded at 03:35 P.M. (As Per BSE Announcement Dated on 24/01/2023)
20-Oct-2022	04-Nov-2022	Quarterly Results	Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2022 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2022. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 October 2022 till the expiry of 48 hours from the date the said financial results are made public. The above information is also being made available on the website of the Company at www.tatvachintan.com. Kindly take above intimation on your record and oblige. Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 04 November 2022. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 01:00 P.M. and concluded at 03:55 P.M. (As Per BSE Announcement dated on 04.11.2022)
15-Jul-2022	25-Jul-2022	Quarterly Results	Quarterly Results Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), we enclose herewith the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2022. The said Results were reviewed and recommended by Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 25 July 2022. Further, we enclose herewith Limited Review Report issued by M/s. NDJ & Co., Chartered Accountants, (Firm Registration No. 136345W), Statutory Auditors of the Company as required under Regulation 33 of Listing Regulations. The above information shall be made available on the website of the Company at www.tatvachintan.com. The Board meeting commenced at 11:30 A.M. and concluded at 03:30 P.M. Kindly take above intimation on your record and oblige. (As per BSE Announcement Dated on 25/07/2022)
16-Apr-2022	25-Apr-2022	Quarterly Results	Tatva Chintan Pharma Chem Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on April 25, 2022, inter alia, to: 1. consider and approve and take on record the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2022; 2. consider and recommend a final dividend, if any, on the equity shares of the Company for the financial year ended March 31, 2022, subject to approval of the shareholders at the ensuing Annual General Meeting of the Company. Further, in accordance with the Company''s Code of Conduct for Prohibition of Insider Trading, the Company has intimated its 'designated persons' regarding the closure of the Trading Window for trading in the Company''s equity shares from April 01, 2022 till the expiry of 48 hours from the date the said financial results are made public. The Board Recommended a Final Dividend of Rs. 2/- (20%) per equity share of Rs. 10/- each fully paid (subject to deduction of tax, if any) on the equity share capital of Rs. 22,16,50,620/- (2,21,65,062 equity shares of Rs. 10/- each) for the financial year 2021-22. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. Outcome Of The Board Meeting Held On 25.04.2022 Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended on 31 March 2022 (As Per BSE Announcement Dated on 25.04.2022) Pursuant to the changes introduced by the Finance Act, 2020, Dividend Distribution Tax has been abolished with effect from 01 April 2020 and the Dividend Income is taxable in the hands of the Shareholders. In this regard, please find enclosed herewith an email communication which has been sent to all the shareholders having their email ID''s registered with the Company / Registrar & Transfer Agent / Depositories explaining the process and documentation required for claiming tax exemption/withholding tax on dividend to the Shareholders at prescribed rates. The above information shall be made available on the website of the Company at www.tatvachintan.com. You are requested to take the same on your records. (As Per BSE Announcement Dated on 09.08.2022)
07-Jan-2022	17-Jan-2022	Quarterly Results	Quarterly Results Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/01/2022 ,inter alia, to consider and approve Pursuant to the Regulation 29 (1) (a) read with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, we hereby inform you that the Meeting of the Board of Directors of Tatva Chintan Pharma Chem Limited is scheduled to be held on Monday, 17 January, 2022, inter alia to: 1.Consider and approve the unaudited standalone financial results of the Company for the quarter/ nine months ended 31 December, 2021. 2.Consider and approve the unaudited consolidated financial results of the Company for the quarter /nine months ended 31 December 2021. Kindly take the above information on your record. Pursuant to Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby disclose the updated contact details of Key Managerial Personnel (KMP) who has been authorized by the Board of Directors at their meeting held on January 17, 2022 of the Company for the purpose of determining materiality of an event or information and of making disclosure of such material information to the stock exchange under these regulations as follows: Sr. No. Name of Key Managerial Personnel Designation Contact Details 1. Mr. Ashok Bothra Chief Financial Officer Contact no:+91 75748 48533 / 34 2. Mr. Ishwar Nayi Company Secretary Contact no:+91 75730 46978 Kindly take the above disclosure on your records. Outcome of the Board Meeting held on January 17, 2022 Unaudited Financials Results For The Quarter And Nine Months Ended December 31, 2021 Pursuant to Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, the Board of Directors in their Meeting held on January 17, 2022, has appointed Mr. Ishwar Nayi (A37444) as Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company with effect from January 17, 2022 in terms of provisions of Section 203 of the Companies Act, 2013 and Rule made there under and Regulation 6 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (As per BSE Announcement Dated on 17/01/2022)
03-Dec-2021	03-Dec-2021	Change in Other Executives	Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015 as amended, we wish to inform that based on recommendation of the Nomination and Remuneration Committee (NRC), the Board of Director of the Company at its meeting held on Friday, 03 December 2021, has appointed Mr Ashok Bothra (Chartered Accountant) as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from 03 December 2021. The disclosure required under Regulation 30 of SEBI (LODR) Regulations, 2015 read with para A of Part A of Schedule III of the said regulations and read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 09 September 2015 is enclosed in Annexure-1 Kindly take the above disclosure on your records.

1 2

LOGIN HERE

Tatva Chintan Pharma Chem Ltd

Board Meeting